It does the job we expected, shipped quickly, and was the best in price compared to competitors.
SML2282
Everolimus
Everolimus
1 of 1 reviewers received a sample product or took part in a promotion
≥95% (HPLC), powder, P-glycoprotein substrate
Synonym(s):
Everolimus, 40-O-(2-Hydroxyethyl)rapamycin, 42-O-(2-Hydroxyethyl)-rapamycin, RAD 001, RAD001, SDZ-RAD, 42-O-(2-Hydroxyethyl)rapamycin
Sign Into View Organizational & Contract Pricing
All Photos(1)
Select a Size
Change View
10 MG
$132.00
50 MG
$554.00
About This Item
Empirical Formula (Hill Notation):
C53H83NO14
CAS Number:
Molecular Weight:
958.22
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Recommended Products
Product Name
Everolimus, ≥95% (HPLC)
Quality Level
assay
≥95% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
shipped in
wet ice
storage temp.
−20°C
SMILES string
O=C(C([C@@]1(O)[C@H](C)CC[C@](C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C2=O)([H])O1)=O)N3[C@H](C(O[C@@]([C@@H](C[C@@]4([H])C[C@@H](OC)[C@H](OCCO)CC4)C)([H])CC([C@H](C)/C=C(C)/[C@@H](O)[C@H]2OC)=O)=O)CCCC3
InChI
1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
InChI key
HKVAMNSJSFKALM-GKUWKFKPSA-N
Gene Information
human ... FKBP1A(2280)
Looking for similar products? Visit Product Comparison Guide
Application
Everolimus has been used as an mechanistic target of rapamycin complex 1 (mTORC1) inhibitor to study its effect on MCF7 and MDA-MB-231 cell lines.[1]
Biochem/physiol Actions
Everolimus, a substrate for P-glycoprotein (P-gp) can be used to treat advanced neuroendocrine tumors (NETs).[2]
Everolimus, the 40-O-(2-hydroxyethyl) derivative of rapamycin (sirolimus), is a potent and selective inhibitor of mechanistic target of rapamycin (mTOR). Everolimus is selective for the mTORC1 protein complex. Everolimus exhibit potent immunosuppressive and anticancer activities.
signalword
Warning
hcodes
Hazard Classifications
Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Repr. 2 - STOT RE 2
target_organs
Kidney,Testes
Storage Class
11 - Combustible Solids
wgk_germany
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Barkovskaya A, et al.
Scientific Reports, 9(1), 5670-5670 (2019)
Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence
Lee L, et al.
Expert Opinion on Pharmacotherapy, 19(8), 909-928 (2018)
Chemical modification of rapamycin: the discovery of SDZ RAD.
R Sedrani et al.
Transplantation proceedings, 30(5), 2192-2194 (1998-09-02)
Heidi A Lane et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 15(5), 1612-1622 (2009-02-19)
Comparison of the antiangiogenic/vascular properties of the oral mammalian target of rapamycin (mTOR) inhibitor RAD001 (everolimus) and the vascular endothelial growth factor receptor (VEGFR) inhibitor vatalanib (PTK/ZK). Antiproliferative activity against various tumor histotypes and downstream effects on the mTOR pathway
Gerke Ariaans et al.
BMC cancer, 17(1), 232-232 (2017-03-31)
Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regularly leads to side-effects including hyperglycemia. The AMPK inhibitor and anti-diabetic drug metformin may counteract everolimus-induced hyperglycemia, as well as enhancing anti-cancer efficacy. We investigated the glucose-dependent
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
